Fagron Announces Growth Strategy for Future Success
Fagron, the leading global player in pharmaceutical compounding, is gearing up to share its ambitious growth strategy and mid-term financial targets during its Capital Markets Day. This highly anticipated event will take place with presentations from key company leaders, including CEO Rafael Padilla and CFO Karin de Jong. They will delve into Fagron's promising strategic direction, financial objectives, and an overview of regional dynamics.
Details of the Compounding for Growth Plan
Fagron's Compounding for Growth plan spans from 2025 to 2030 and emphasizes significant organic revenue growth along with an impressive margin trajectory. The company's plan outlines:
- Organic revenue CAGR at CER: targeting high single digit to low double digit growth
- Expectations of a REBITDA margin reaching approximately 21% by 2027, with continued growth through 2030
- Operating cash flow conversion rates pegged at 70% or higher
- Free cash flow conversion rates expected to be at least 50%, excluding one-off capital expenses
- Capital expenditure as a percentage of revenue set at 3.5%
- Aiming for a net debt to EBITDA ratio target of 2.8x, with a maximum leverage of 3.5x
- A capital allocation strategy dedicated to value creation via organic investments, mergers and acquisitions, and maintaining an attractive dividend policy.
During the announcement, CEO Rafael Padilla expressed enthusiasm about the company's future. He stated, "Today marks the initiation of our next phase—characterized by strategic clarity, disciplined execution, and financial ambition. We foresee a direct path toward enhancing our growth profile. For the 2025-2030 timeline, we are targeting a high single digit to low double digit organic revenue growth CAGR while ensuring margin expansion and persistent cash generation."
Regional Growth Expectations
Fagron's forecasting reflects a positive outlook across various regions. The company anticipates:
EMEA: Expected to grow in the mid-single digits.
Latin America: Expected to increase in the high-single digits.
North America: Forecasted to enjoy growth in the low to mid-teens.
This growth is attributed to Fagron's robust market position, increasing demand for personalized medicine, and excellent operational capabilities. The anticipated acceleration stems from an uptick in Compounding Services outpacing Brands and Essentials, with Brands expected to outperform Essentials.
Operational Excellence and Margin Improvement
The aim is to reach a REBITDA margin of about 21% by 2027, supported by Fagron's ongoing Operational Excellence initiatives, a strong contribution from its Global Brands Strategy, and the advantages gained from enhanced operational leverage.
Moving forward, Fagron is committed to maintaining high cash-generating potential and will approach capital deployment strategically, with Capex set at 3.5% of revenue. The company views M&A as a vital engine for value creation, looking to consolidate markets, improve product capabilities, and expand geographic presence.
Strategic Overview for 2025 - 2030
Fagron's strategy is centered around four main focal points designed to enhance its leadership in pharmaceutical compounding and deliver sustainable value:
1. Strengthen Global Leadership in Essentials
Fagron will continue its dominance in repackaging and distributing pharmaceutical raw materials while focusing on enhanced operational excellence.
2. Accelerate Growth in Brands
The Global Brands Strategy is set to be a primary growth driver, expanding its share of B&E revenue by globally scaling proven Brands with scientific backing.
3. Expand Sterile Compounding Services
The company is making significant investments in sterile capacity and capabilities to establish itself as a leading provider of personalized sterile medicines.
4. Optimize Non-Sterile Compounding and Registration Business
In non-sterile compounding, Fagron aims to improve margins through operational efficiencies and a refined registration business focused on high-value market segments.
All these strategic efforts are supported by targeted investments and a globally aligned leadership committed to executing effective long-term value creation.
Connect Live via Webcast
The Capital Markets Day will be accessible through a live video webcast, allowing stakeholders to follow along. This will provide an excellent platform for transparency and engagement. All presentations will be downloadable from Fagron's official website shortly after the event's conclusion.
Contact Information
For any inquiries, please reach out to:
Ignacio Artola
Global Investor Relations Leader
Tel: +34 670 385 795
Email: ignacio.artola@fagron.com
About Fagron
Fagron is a premier global company in the pharmaceutical compounding industry, dedicated to providing personalized medication solutions to healthcare facilities and patients across more than 30 countries worldwide.
Based in Belgium, Fagron NV operates under the ticker symbol ‘FAGR’ on both Euronext Brussels and Euronext Amsterdam, with its operational management undertaken by the Dutch subsidiary Fagron BV headquartered in Rotterdam.
Frequently Asked Questions
What is Fagron's growth strategy for 2025-2030?
Fagron aims for high single digit to low double digit organic revenue growth, along with improving its REBITDA margin to approximately 21% by 2027.
Who are the key speakers at the Capital Markets Day?
The event features presentations from CEO Rafael Padilla, CFO Karin de Jong, and various regional and functional leaders.
What regions are expected to see growth?
Fagron anticipates growth in EMEA, Latin America, and North America, with specific projections ranging from the mid-single digits to low-mid teens.
What is the focus of Fagron's operational initiatives?
Fagron is prioritizing operational excellence, expanding its brands, and enhancing capabilities in sterile compounding services among other strategic focuses.
How can stakeholders engage with Fagron during the event?
Stakeholders can participate through a live video webcast and access downloadable presentations from Fagron’s official website.
